Drug intelligence / Profile preview

PURamnio

Development stage: Unknown
Lead developer: HippoFi
Administration: Local Injection, Topical

Overview

PURamnio is an amniotic-derived orthobiologic product developed by PUR Biologics, a subsidiary of HippoFi. Launched for commercial distribution in early 2024, it is designed for use in regenerative medicine applications, particularly within orthopedic and spinal surgery. The product leverages the biological properties of amniotic tissue, which contains a high concentration of regenerative components such as growth factors, cytokines, and extracellular matrix proteins. These components work synergistically to promote tissue repair, reduce inflammation, and provide a biological scaffold for healing. It is typically utilized as an allograft in surgical settings to enhance recovery and improve clinical outcomes in musculoskeletal conditions. It is distinct from the infant formula product PurAmino.

Brand names: PURamnio

Beyond the preview

Go deeper on PURamnio.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PURamnio.

Explore the full profile